FUSILEV
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Mar 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUSILEV is an intravenous solution approved in 2008 for Non-Small Cell Lung Cancer and Non-Hodgkin's Lymphoma. The mechanism of action and specific pharmacologic class are not publicly detailed in available data. It represents a mature oncology therapeutic in a market dominated by newer targeted and immunotherapy agents.
LOE Approaching
As a 16-year-old product approaching loss of exclusivity, the brand team is likely focused on lifecycle extension and managing competitive erosion rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Started Apr 2013
0Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Started Mar 2013
0Non Hodgkin's Lymphoma
Career Relevance
Working on FUSILEV offers limited career growth relative to peak-stage oncology franchises; roles focus on defensive positioning, payer negotiation, and retention in a contracting market. This assignment is best suited for professionals seeking stability and execution expertise in mature product management rather than innovation-driven advancement.
Worked on FUSILEV at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.